首页/数据集/Sensitivity, specificity, and accuracy of pancreatic cancer diagnosis by CB vs. CB with K-ras mutation analysis.

Sensitivity, specificity, and accuracy of pancreatic cancer diagnosis by CB vs. CB with K-ras mutation analysis.

Figshare2018-03-02 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Sensitivity_specificity_and_accuracy_of_pancreatic_cancer_diagnosis_by_CB_vs_CB_with_i_K-ras_i_mutation_analysis_/5941876 数据链接链接失效反馈

官方服务：

资源简介：

Sensitivity, specificity, and accuracy of pancreatic cancer diagnosis by CB vs. CB with K-ras mutation analysis.

应用场景：

创建时间：

2018-03-02

结直肠癌靶向治疗

RAS突变分析

Interventions: TFTD: 35 mg/m. given orally twice daily on days 1-5 and 8-12 in a 28-day cycle Bevacizumab: 5 mg/kg, administered by intravenous infusion for 30 min every 2 weeks Primary outcome(s): Di

NIAID Data Ecosystem40

Supplementary Material for: Noonan Syndrome: Comparing Mutation-Positive with Mutation-Negative Dutch Patients

遗传病基因型-表型关联

RAS突变分析

Noonan syndrome (NS) is an autosomal dominant disorder characterized by facial dysmorphisms, short stature and congenital heart defects. The disorder is genetically heterogeneous and shows clinical ov

NIAID Data Ecosystem30

Clinical, pathological and immunohistochemical findings in colorectal cancer cases with novel K-ras mutations compared to cases with other K-ras mutations.

结直肠癌基因组学

RAS突变分析

Clinical, pathological and immunohistochemical findings in colorectal cancer cases with novel K-ras mutations compared to cases with other K-ras mutations.

NIAID Data Ecosystem20

Expression profile of exosomal LncRNA in plasma of pancreatic ductal adenocarcinoma

外泌体非编码RNA表达谱

胰腺癌分子诊断

Background:Exosomes are extracellular vesicles secreted by a variety of cells and are widely distributed in human body fluids. Exosomal long non-coding RNA (lncRNA) is a by-product of gene transcripti

NIAID Data Ecosystem30

PhaseII study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapy (JFMC51-1702-C7)

结直肠癌靶向治疗

RAS突变分析

Interventions: TFTD: 35 mg/m. given orally twice daily on days 1-5 and 8-12 in a 28-day cycle, Bevacizumab: 5 mg/kg, administered by intravenous infusion for 30 min every 2 weeks Primary outcome(s):

NIAID Data Ecosystem30

Sensitivity, specificity, and accuracy of pancreatic cancer diagnosis by CB vs. CB with K-ras mutation analysis.

资源简介：

相关数据集